August 15, 2025

Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.

View Full Paper

Ask AI

Bookmark

Authors

LWLulu WangNanjing University of Chinese Medicine PZPeng ZhaoWuhan University JLJing LiuQingdao University

Discussion

Member takes

Implication

This analysis reveals that peritransplant MRD dynamics predict overall survival and relapse risk in adults with acute myeloid leukemia, indicating its potential as a key prognostic marker.

Key Points

MRD dynamics during the peritransplant period significantly impact outcomes in adult acute myeloid leukemia with KMT2Ar.
The MRD-negative/MRD-negative group showed the highest 3-year overall survival rate at 88%, while MRD-positive groups had poor outcomes.
The study involved 144 adult AML patients who underwent allogeneic hematopoietic stem cell transplantation from 2015 to 2024.
Peritransplant MRD testing demonstrated superior prognostic accuracy compared to single-time point assessments, aiding risk stratification.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/689fc3ee735da01f534db99f https://doi.org/10.1002/cncr.70044

View Full Paper

Ask AI

Bookmark

Implication

This analysis reveals that peritransplant MRD dynamics predict overall survival and relapse risk in adults with acute myeloid leukemia, indicating its potential as a key prognostic marker.

Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.

Discussion

Member takes

Implication

Key Points

Cite This Study

Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider